Adam Brufsky, MD, PhD, University of Pittsburgh, Pittsburgh, PA, talks on remaining questions regarding management of HER2-low breast cancer, primarily whether the definition of HER2-low disease can be expanded to include patients with particularly low levels of HER2. The answer may be found in Phase III DESTINY-Breast06 (NCT04494425) clinical trial, which is investigating trastuzumab deruxtecan (T-DXd) versus investigator's choice chemotherapy in patients with ultra-low HER2 breast cancer. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
